Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

NDAQ:LEXX - Post Discussion

View:
Post by SkyLight8 on Sep 27, 2021 6:32pm

get ready

easy 14-16$ tag comimg or a lousy 80 million cap
Comment by WakeUPP on Sep 28, 2021 12:38pm
skylight what is going on?  MOTNHS ago you said it would be $20 by monday, then you said $15, then you  said $25, then you said $14.  Does spaming it day after day after day using PILEs of ids, posting it oin twitter ten quoting YOURSELF as if you were someone different(lol) make it likely to happen?  Looks like the stock is heading down to me, barely over where they fiananced.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities